MCM
FPRX

Mazama Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Mazama Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,088
Closed -$40K – 289
2013
Q3 		$40K Buy
+3,088
New +$41.8K 0.02% 167

Other funds holding FPRX

WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Mazama Capital Management's FPRX Position: Q4 2013 in Review

Mazama Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2013, closing a stake of 3,088 shares — an estimated $40K sold.

Mazama Capital Management first reported a position in FPRX in Q3 2013 and held it in 1 quarter. The position peaked at $40K in Q3 2013. 42 funds tracked by Wall St. Rank hold FPRX as of Q4 2013.

  • Mazama Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Mazama Capital Management sold 3,088 Five Prime Therapeutics, Inc. shares in Q4 2013, an estimated $40K.
  • Mazama Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • Mazama Capital Management's Five Prime Therapeutics, Inc. position peaked at $40K in Q3 2013.
  • 42 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2013.

Based on Mazama Capital Management's 13F filing for Q4 2013, filed 10 Feb 2014.